头孢哌酮/舒巴坦钠与亚胺培南/西司他丁钠治疗肺部感染最小成本分析  

Cost-Minimization Analysis on Cefoperazone/Sulbactam Sodium and Imipenem for Injection/ Cilastatin Sodium for Pulmonary Infection

作　　者：裴保香[1] 金杨红[2] 单文治[1] 

机构地区：[1]解放军总医院药品保障中心,北京100853 [2]安徽蚌埠医学院,蚌埠233010

出　　处：《中国医院用药评价与分析》2011年第8期724-726,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价头孢哌酮/舒巴坦钠(舒普深,CPZ-SB)与亚胺培南/西司他丁钠(泰能I,MP)治疗肺部感染的经济学效果。方法:运用最小成本分析法,对分别以2种治疗方案治疗肺部感染的临床疗效及成本进行评价。结果:CPZ-SB组和IMP组总有效率分别为92.68%、78.05%,细菌清除率分别为57.14%、50%,均无统计学意义(P>0.05)。CPZ-SB组和IMP组的治疗成本分别为3 184.55、1 732.65元,成本-效果比分别为34.362、2.20。结论:从药物经济学角度看I,MP组方案较佳。OBJECTIVE：To evaluate the economic effects of cefoperazone/sulbactam sodium（CPZ-SB） vs.imipenem for injection/cilastatin sodium（IMP） for pulmonary infection.METHODS：The therapeutic effects and costs of the two therapeutic schemes for pulmonary infection were evaluated by using cost-minimization analysis.RESULTS：The total effective rates of CPZ-SB and IMP were 92.68% and 78.05%,respectively,with germ-clearance rates of 57.14% and 50%,respectively（P0.05）.The total costs of CPZ-SB and IMP schemes were 3 184.55 Yuan and 1 732.65 Yuan,respectively,and the cost-effectiveness ratios were 34.36 and 22.20,respectively.CONCLUSION：Pharmacoeconomically,IMP scheme was superior to CPZ-SB for pulmonary infection.

关 键 词：头孢哌酮/舒巴坦钠(舒普深) 亚胺培南/西司他丁钠(泰能) 最小成本分析 肺部感染 药物经济学 

分 类 号：R978.1[医药卫生—药品]